411. Phase 1/2 Trial of an Investigational Herpes Zoster Vaccine with CpG 1018® Adjuvant and Shingrix in Healthy Adults 50 to 69 Years of Age

Le résumé fourni par la source

Abstract Background Herpes zoster (shingles) affects older adults due to waning cellular immunity. Z-1018, a CpG 1018®–adjuvanted gE subunit vaccine, is being developed to elicit efficacy comparable to Shingrix while offering improved tolerability. In a prior phase 1 trial, a CpG 1018®-adjuvanted vaccine with fixed-dosage commercial gE showed lower reactogenicity and comparable vaccine response rates (VRRs) to Shingrix.Table 1:Anti-gE IgG Response at 4 Weeks Post Dose 2 (Per-Protocol Immunogenicity Analysis Population)Participants who received 2 vaccine doses, had no major protocol deviations, and had CD4+ T-cell assessment within the protocol-defined window. Groups (all Z-1018 groups used 6000 µg CpG 1018®/dose): 50/12: 50 mcg gE (0, 12 weeks); 50A/12: 50 mcg gE + Alum (0, 12 weeks); 100/12: 100 mcg gE (0, 12 weeks); 100/08: 100 mcg gE (0, 8 weeks); 100A/12: 100 mcg gE + Alum (0, 12 weeks); 100A/08: 100 mcg gE + Alum (0, 8 weeks); 200/12: 200 mcg gE (0, 12 weeks); 200/08: 200 mcg gE (0, 8 weeks); 200A/12: 200 mcg gE + Alum (0, 12 weeks); 200A/08: 200 mcg gE + Alum (0, 8 weeks); Shingrix (0, 8 and 0, 12 weeks). VRR=% participants with ≥4-fold increase in anti-gE IgG concentration from pre-vaccination baseline Methods In an ongoing, randomized, observer-blinded phase 1/2 trial, adults ages 50–69 received 2 doses of Z-1018 (50, 100, or 200 µg Dynavax-manufactured gE adjuvanted with 6000 µg CpG 1018® with/without 750 µg alum) given at an 8- or 12-week interval or Shingrix (10:1) at the same interval. Adverse events, post-injection reactions (PIRs) within 7 days, and immunogenicity (anti-gE IgG and activated gE-specific CD4⁺ T-cell responses) at 4 weeks after the second dose were evaluated. VRRs were defined as participants (%) with ≥4-fold increase in anti-gE IgG concentration over baseline and, separately, ≥2-fold increase in CD4⁺ T-cell frequency over baseline. Results Among 441 participants (median age 58.0 years; 68.3% female), Z-1018 groups had lower rates of moderate-or-severe PIRs than Shingrix (local: 7.7–35.0% vs 52.6% for Shingrix; systemic: 17.5–46.2% vs 63.2% for Shingrix). No safety concerns were observed or reported. Anti-gE IgG VRRs (96.7–100%), and GMCs observed for the 100 µg and 200 µg gE formulations, were comparable to, and in some cases exceeded, those for Shingrix (Table 1). CD4+ data will be available for presentation at IDWeek. Conclusion Z-1018 adjuvanted with 6000 µg CpG 1018® +/- alum showed favorable tolerability and strong anti-gE IgG responses across a range of gE dosage levels and dosing intervals. These interim data support continued clinical development of Z-1018. Final trial results will be reported at a later date. Disclosures All Authors: No reported disclosures

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.